TW201142292A - Cancer patient selection for administration of therapeutic agents using mass spectral analysis of blood-based samples - Google Patents

Cancer patient selection for administration of therapeutic agents using mass spectral analysis of blood-based samples Download PDF

Info

Publication number
TW201142292A
TW201142292A TW100106286A TW100106286A TW201142292A TW 201142292 A TW201142292 A TW 201142292A TW 100106286 A TW100106286 A TW 100106286A TW 100106286 A TW100106286 A TW 100106286A TW 201142292 A TW201142292 A TW 201142292A
Authority
TW
Taiwan
Prior art keywords
combination
benefit
egfr
therapeutic
cancer
Prior art date
Application number
TW100106286A
Other languages
English (en)
Chinese (zh)
Inventor
Julia Grigorieva
Heinrich Roder
Maxim Tsypin
Original Assignee
Biodesix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biodesix Inc filed Critical Biodesix Inc
Publication of TW201142292A publication Critical patent/TW201142292A/zh

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/70—Machine learning, data mining or chemometrics
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
    • H01J49/00—Particle spectrometers or separator tubes
    • H01J49/26—Mass spectrometers or separator tubes
    • H01J49/34—Dynamic spectrometers
    • H01J49/40—Time-of-flight spectrometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/20—Identification of molecular entities, parts thereof or of chemical compositions
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
    • H01J49/00—Particle spectrometers or separator tubes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Artificial Intelligence (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Evolutionary Computation (AREA)
  • Medical Informatics (AREA)
  • Software Systems (AREA)
TW100106286A 2010-02-24 2011-02-24 Cancer patient selection for administration of therapeutic agents using mass spectral analysis of blood-based samples TW201142292A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33893810P 2010-02-24 2010-02-24

Publications (1)

Publication Number Publication Date
TW201142292A true TW201142292A (en) 2011-12-01

Family

ID=44477214

Family Applications (1)

Application Number Title Priority Date Filing Date
TW100106286A TW201142292A (en) 2010-02-24 2011-02-24 Cancer patient selection for administration of therapeutic agents using mass spectral analysis of blood-based samples

Country Status (9)

Country Link
US (2) US20110208433A1 (enExample)
EP (1) EP2539704A4 (enExample)
JP (2) JP2013520681A (enExample)
KR (1) KR101556726B1 (enExample)
CN (1) CN102770760A (enExample)
AU (2) AU2011219069C1 (enExample)
CA (1) CA2790928A1 (enExample)
TW (1) TW201142292A (enExample)
WO (1) WO2011106084A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI639001B (zh) 2012-06-26 2018-10-21 美商拜歐迪希克斯公司 用於選擇及淘汰癌症病人接受免疫反應產生療法之質譜方法

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014505257A (ja) * 2011-01-28 2014-02-27 バイオデシックス・インコーポレイテッド ホルモン療法および組み合わせ療法のための転移性乳癌患者の選択の予測試験
EP3096142A3 (en) * 2011-04-29 2017-03-08 Celgene Corporation Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
WO2013180818A2 (en) 2012-05-29 2013-12-05 Biodesix, Inc. Deep-maldi tof mass spectrometry of complex biological samples, e.g., serum, and uses thereof
WO2014007859A1 (en) * 2012-07-05 2014-01-09 Biodesix, Inc. Method for predicting whether a cancer patient will not benefit from platinum-based chemotherapy agents
US9211314B2 (en) 2014-04-04 2015-12-15 Biodesix, Inc. Treatment selection for lung cancer patients using mass spectrum of blood-based sample
WO2015157109A1 (en) * 2014-04-08 2015-10-15 Biodesix, Inc. Egfr and hgf inhibitor therapy for lung cancer
WO2016054031A1 (en) * 2014-10-02 2016-04-07 Biodesix, Inc. Predictive test for aggressiveness or indolence of prostate cancer from mass spectrometry of blood-based sample
US11594403B1 (en) 2014-12-03 2023-02-28 Biodesix Inc. Predictive test for prognosis of myelodysplastic syndrome patients using mass spectrometry of blood-based sample
US10037874B2 (en) 2014-12-03 2018-07-31 Biodesix, Inc. Early detection of hepatocellular carcinoma in high risk populations using MALDI-TOF mass spectrometry
US11152197B2 (en) * 2015-06-24 2021-10-19 City University Of Hong Kong Method of determining cell cycle stage distribution of cells
CN112710723B (zh) * 2015-07-13 2024-11-12 佰欧迪塞克斯公司 受益于pd-1抗体药物的肺癌患者的预测性测试和分类器开发方法
US11710539B2 (en) 2016-02-01 2023-07-25 Biodesix, Inc. Predictive test for melanoma patient benefit from interleukin-2 (IL2) therapy
CN106596824A (zh) * 2016-12-30 2017-04-26 广州中大南沙科技创新产业园有限公司 一种lc‑ms/ms法检测血浆中沙利度胺的方法
CN110383069A (zh) 2017-01-05 2019-10-25 佰欧迪塞克斯公司 用于鉴定总体不良预后亚组中持久受益于免疫疗法的癌症患者的方法
CN109212042B (zh) * 2017-06-30 2022-03-04 齐鲁制药有限公司 一种采用液质联用法测定盐酸培唑帕尼基因毒性杂质的分析方法
KR102633621B1 (ko) 2017-09-01 2024-02-05 벤 바이오사이언시스 코포레이션 진단 및 치료 모니터링용 바이오마커로서의 당펩티드의 식별 및 용도
EP3724885A2 (en) 2017-12-15 2020-10-21 Iovance Biotherapeutics, Inc. Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
WO2019190732A1 (en) * 2018-03-29 2019-10-03 Biodesix, Inc. Apparatus and method for identification of primary immune resistance in cancer patients
WO2020019095A1 (es) * 2018-07-26 2020-01-30 Universidad Católica Del Maule Proteína rage (receptor de productos finales de glicacíon avanzada) como biomarcador de sensibilidad tumoral y evaluacion de terapia radiologica y radiomimética
CN119139478A (zh) * 2024-10-11 2024-12-17 首都医科大学附属北京胸科医院 一种治疗anxa6+egfr突变的肺腺癌的组合物

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4802102A (en) * 1987-07-15 1989-01-31 Hewlett-Packard Company Baseline correction for chromatography
US5291426A (en) * 1991-02-27 1994-03-01 The Perkin-Elmer Corporation Method of correcting spectral data for background
ES2070739B1 (es) * 1993-04-30 1997-06-01 Alcatel Standard Electrica Dispositivo de conversion de interfaces.
US20030108545A1 (en) * 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
US6017693A (en) * 1994-03-14 2000-01-25 University Of Washington Identification of nucleotides, amino acids, or carbohydrates by mass spectrometry
US5672869A (en) * 1996-04-03 1997-09-30 Eastman Kodak Company Noise and background reduction method for component detection in chromatography/spectrometry
US6253162B1 (en) * 1999-04-07 2001-06-26 Battelle Memorial Institute Method of identifying features in indexed data
IL153189A0 (en) * 2000-06-19 2003-06-24 Correlogic Systems Inc Heuristic method of classification
CA2414610A1 (en) * 2000-07-13 2002-01-24 Medi-Physics, Inc. Diagnostic procedures using 129xe spectroscopy characteristic chemical shift to detect pathology in vivo
SG144731A1 (en) * 2000-07-18 2008-08-28 Correlogic Systems Inc A process for discriminating between biological states based on hidden patterns from biological data
AU2002241535B2 (en) * 2000-11-16 2006-05-18 Ciphergen Biosystems, Inc. Method for analyzing mass spectra
US20020119490A1 (en) * 2000-12-26 2002-08-29 Aebersold Ruedi H. Methods for rapid and quantitative proteome analysis
US20020115056A1 (en) * 2000-12-26 2002-08-22 Goodlett David R. Rapid and quantitative proteome analysis and related methods
US6829539B2 (en) * 2001-04-13 2004-12-07 The Institute For Systems Biology Methods for quantification and de novo polypeptide sequencing by mass spectrometry
US6849121B1 (en) * 2001-04-24 2005-02-01 The United States Of America As Represented By The Secretary Of The Air Force Growth of uniform crystals
US7314717B2 (en) * 2001-04-30 2008-01-01 Nanogen Inc. Biopolymer marker indicative of disease state having a molecular weight of 1562 daltons
US7113896B2 (en) * 2001-05-11 2006-09-26 Zhen Zhang System and methods for processing biological expression data
US6675106B1 (en) * 2001-06-01 2004-01-06 Sandia Corporation Method of multivariate spectral analysis
US7112408B2 (en) * 2001-06-08 2006-09-26 The Brigham And Women's Hospital, Inc. Detection of ovarian cancer based upon alpha-haptoglobin levels
WO2003006951A2 (en) * 2001-07-13 2003-01-23 Syngenta Participations Ag System and method of determining proteomic differences
US7016884B2 (en) * 2002-06-27 2006-03-21 Microsoft Corporation Probability estimate for K-nearest neighbor
WO2004019003A2 (en) * 2002-08-23 2004-03-04 Efeckta Technologies Corporation Image processing of mass spectrometry data for using at multiple resolutions
US20040147428A1 (en) * 2002-11-15 2004-07-29 Pluenneke John D. Methods of treatment using an inhibitor of epidermal growth factor receptor
US6906320B2 (en) * 2003-04-02 2005-06-14 Merck & Co., Inc. Mass spectrometry data analysis techniques
JP2007506442A (ja) * 2003-05-30 2007-03-22 ゲノミック ヘルス， インコーポレイテッド Ｅｇｆｒ阻害薬への応答に関する遺伝子発現マーカー
US20050267689A1 (en) * 2003-07-07 2005-12-01 Maxim Tsypin Method to automatically identify peak and monoisotopic peaks in mass spectral data for biomolecular applications
US20050048547A1 (en) * 2003-07-17 2005-03-03 Hongyu Zhao Classification of disease states using mass spectrometry data
SG145705A1 (en) * 2003-08-01 2008-09-29 Correlogic Systems Inc Multiple high-resolution serum proteomic features for ovarian cancer detection
EP1709442A4 (en) * 2003-12-11 2010-01-20 Correlogic Systems Inc METHOD FOR DIAGNOSING BIOLOGICAL CONDITIONS BY USING A CENTRALIZED ADAPTIVE MODEL AND SAMPLE PREPARATION
ES2244326B1 (es) * 2004-04-05 2007-02-16 Laboratorios Del Dr. Esteve, S.A. Combinacion de substancias activas.
JP2008501654A (ja) * 2004-06-03 2008-01-24 エフ．ホフマン−ラ　ロシュ　アーゲー シスプラチンとｅｇｆｒ阻害剤を用いた治療
US20060029574A1 (en) * 2004-08-06 2006-02-09 Board Of Regents, The University Of Texas System Biomarkers for diagnosis, prognosis, monitoring, and treatment decisions for drug resistance and sensitivity
SI1948180T1 (sl) * 2005-11-11 2013-06-28 Boehringer Ingelheim International Gmbh Kombinacijsko zdravljenje raka, ki obsega EGFR/HER2 inhibitorje
US7858389B2 (en) * 2006-03-31 2010-12-28 Biodesix, Inc. Selection of non-small-cell lung cancer patients for treatment with monoclonal antibody drugs targeting EGFR pathway
US7906342B2 (en) * 2006-03-31 2011-03-15 Biodesix, Inc. Monitoring treatment of cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples
US7858390B2 (en) * 2006-03-31 2010-12-28 Biodesix, Inc. Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathway
US7736905B2 (en) * 2006-03-31 2010-06-15 Biodesix, Inc. Method and system for determining whether a drug will be effective on a patient with a disease
US7867775B2 (en) * 2006-03-31 2011-01-11 Biodesix, Inc. Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway
JP2010508512A (ja) * 2006-10-27 2010-03-18 ジョージ メイソン インテレクチュアル プロパティーズ，インコーポレイテッド オブ フェアファックス，バージニア 転移性結腸直腸癌のアッセイ
CN101201355A (zh) * 2006-12-15 2008-06-18 许洋 免疫组质谱检测个体化肿瘤生物标志及疗效试剂盒和方法
ES2412432T3 (es) * 2007-02-27 2013-07-11 Nuclea Biomarkers Llc Método para predecir la respuesta de pacientes de nsclc al tratamiento mediante un inhibidor de egfr-tk
CN101329346A (zh) * 2007-06-18 2008-12-24 许洋 检测乳腺癌特征蛋白的优化质谱模型及其制备方法和应用
WO2009036123A1 (en) * 2007-09-11 2009-03-19 Cancer Prevention And Cure, Ltd. Method of identifying biomarkers in human serum indicative of pathologies of human lung tissues
CN101836991B (zh) * 2009-03-19 2013-05-22 鼎泓国际投资（香港）有限公司 含有索拉非尼、cMet抑制剂与EGFR酪氨酸激酶抑制剂的药物组合物及其应用
WO2014007859A1 (en) * 2012-07-05 2014-01-09 Biodesix, Inc. Method for predicting whether a cancer patient will not benefit from platinum-based chemotherapy agents

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI639001B (zh) 2012-06-26 2018-10-21 美商拜歐迪希克斯公司 用於選擇及淘汰癌症病人接受免疫反應產生療法之質譜方法

Also Published As

Publication number Publication date
AU2011219069A1 (en) 2012-09-13
US20140284468A1 (en) 2014-09-25
KR101556726B1 (ko) 2015-10-02
EP2539704A4 (en) 2015-12-02
EP2539704A1 (en) 2013-01-02
US20110208433A1 (en) 2011-08-25
CA2790928A1 (en) 2011-09-01
JP2015222257A (ja) 2015-12-10
AU2014202716B2 (en) 2016-02-25
AU2011219069C1 (en) 2014-07-17
WO2011106084A1 (en) 2011-09-01
JP2013520681A (ja) 2013-06-06
AU2014202716A1 (en) 2014-06-12
CN102770760A (zh) 2012-11-07
KR20130004309A (ko) 2013-01-09
AU2011219069B2 (en) 2014-02-20

Similar Documents

Publication Publication Date Title
TW201142292A (en) Cancer patient selection for administration of therapeutic agents using mass spectral analysis of blood-based samples
Solanki et al. Cell type–specific adaptive signaling responses to KRASG12C inhibition
Loboda et al. A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors
TW201028688A (en) Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway
AU2009338173B2 (en) Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathway
US20120225954A1 (en) Methods and compositions for the classification of non-small cell lung carcinoma
Rodriguez-Vida et al. Predictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinoma
TW201237409A (en) Predictive test for selection of metastatic breast cancer patients for hormonal and combination therapy
Wang et al. Phosphoproteomics reveals HMGA1, a CK2 substrate, as a drug-resistant target in non-small cell lung cancer
US20150285817A1 (en) Method for treating and identifying lung cancer patients likely to benefit from EGFR inhibitor and a monoclonal antibody HGF inhibitor combination therapy
KR102067327B1 (ko) 최적의 암 치료를 위한 Her2 단백질 정량
Asmussen et al. MEK-dependent negative feedback underlies BCR–ABL-mediated oncogene addiction
WO2020046966A1 (en) Treatment of adenocarcinomas with mapk pathway inhibitors
Miao et al. Platelet infiltration predicts survival in postsurgical colorectal cancer patients
TWI567391B (zh) 辨識早期肺腺癌病患之次群組之生物標記
Li et al. EGFR and COX-2 protein expression in non-small cell lung cancer and the correlation with clinical features
Dong et al. Mutant RB1 enhances therapeutic efficacy of PARPis in lung adenocarcinoma by triggering the cGAS/STING pathway
Sevrin et al. Cell-specific models reveal conformation-specific RAF inhibitor combinations that synergistically inhibit ERK signaling in pancreatic cancer cells
El Hassouni et al. Uridine cytidine kinase 2 as a potential biomarker for treatment with RX-3117 in pancreatic cancer
Yu et al. SLC2A1 boosts the resistance of non-small cell lung cancer to taxanes by stimulating the formation of EPCAM+ cancer stem-like cells via glycolysis
Bijman et al. Inhibition of functional HER family members increases the sensitivity to docetaxel in human ovarian cancer cell lines
Kim et al. Proteogenomic characterization identifies clinical subgroups in EGFR and ALK wild-type never-smoker lung adenocarcinoma
Drummond et al. Perioperative IDH inhibition in treatment-naive IDH-mutant glioma: a pilot trial
B. Allela et al. Emerging Insights into TIM-3: A Potential Immune Checkpoint for Lung Cancer Immunotherapeutic Strategies
Teng et al. Leupaxin: A Prospective Therapeutic Target for Esophageal Squamous Carcinoma Treatment